Isradipine

Isradipine

DEA Class; Rx

Common Brand Names; DynaCirc

  •  Calcium Channel Blockers; 
  • Calcium Channel Blockers, Dihydropyridine
Dihydropyridine calcium-channel blocker
Used for hypertension and angina
More potent than nifedipine and amlodipine; longer-acting than regular-release nifedipine but shorter-acting than amlodipine

Indicated for the treatment of hypertension.

For the treatment of chronic stable angina.
For the treatment of hypertensive urgency.

Hypersensitivity to isradipine or other calcium channel blockers; hypotension (<90 mm Hg systolic)

  • Headache (2-22%)
  • Edema (1-9%)
  • Dizziness (2-8%)
  • Palpitation (1-5%)
  • Flushing (1-5%)
  • Tachycardia (1-3%)
  • Chest pain (2-3%)
  • Rash (2%)
  • Nausea (1-5%)
  • Vomiting (≤1%)
  • Diarrhea (≤ 3%)
  • Weakness (≤1%)
  • Dyspnea (1-3%)
  • Urinary frequency (1-3%)
  • Drug-induced gingival hyperplasia
  • Angioedema
  • Drowsiness
  • Hyperhidrosis
  • Leg pain
  • Nasal congestion
  • Drug fever
  • Dysuria
  • Impotence
  • Pruritus
  • Urticaria
  • Weight gain
  • Myocardial infarction

Use caution in CHF, aortic stenosis, hypotension (initially or after dose increases), persistent progressive dermatologic reactions, exacerbation of angina (during initiation of treatment, after dose increase, or withdrawal of beta blocker), liver impairment

Reflex tachycardia resulting in angina and/or MI in patients with obstructive coronary disease reported

Peripheral edema may occur within 2-3 weeks of initiating therapy

Hypotension with or without syncope is possible (particularly with severe aortic stenosis)

Avoid taking with grapefruit juice

Pregnancy Category: C

Lactation: not known if excreted into breast milk

Adults

20 mg/day PO.

Geriatric

20 mg/day PO.

Adolescents

Safety and efficacy have not been established; however, doses up to 0.6 to 0.8 mg/kg/day PO, not to exceed 10 to 20 mg/day PO, have been recommended.

Children

Safety and efficacy have not been established; however, doses up to 0.6 to 0.8 mg/kg/day PO, not to exceed 10 to 20 mg/day PO, have been recommended.

Infants

Safety and efficacy have not been established; however, a mean dose of 0.27 +/- 0.11 mg/kg/day PO has been reported.

Neonates

Safety and efficacy have not been established; however, a mean dose of 0.27 +/- 0.11 mg/kg/day PO has been reported.

Isradipine

capsule

  • 2.5mg
  • 5mg

tablet, extended release

  • 5mg
  • 10mg
DrugsAce
Logo